Latest News

BMO downgrades Biogen, asserts company is spending too much on controversial Alzheimer’s drug

0

Biogen’s new Alzheimer’s drug aduhelm saw limited pickup in its first few months on the market.

Cathie Wood’s Ark Files for New Fund

Previous article

A Meta-morphosis of sentiment that may turn again: Morning Brief

Next article

You may also like

Comments

Leave a reply

Your email address will not be published. Required fields are marked *

More in Latest News